INNER CITY ASTHMA CONSORTIUM, ASTHMA CONTROL EVALUATION (ACE)

内城哮喘协会，哮喘控制评估 (ACE)

• 批准号: 7608371
• 负责人: STEPHEN John TEACH
• 金额: $ 9.88万
• 依托单位: CHILDREN'S RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608371
• 关键词: Adherence; Allergens; Asthma; Biological Markers; Characteristics; Child; Clinical Management; Clinical Treatment; Computer Retrieval of Information on Scientific Projects Database; Devices; Education; Evaluation; Exhalation; Funding; Grant; Guidelines; Immune; Immunomodulators; Inflammation; Institution; Investigation; Low income; Measurement; Measures; Monitor; National Institute of Allergy and Infectious Disease; Nitric Oxide; Pathogenesis; Pharmaceutical Preparations; Pharmacogenetics; Prevention; Prevention program; Protocols documentation; Research; Research Personnel; Resources; Role; Source; Symptoms; Therapeutic; Treatment Protocols; United States National Institutes of Health; anti-IgE; base; design; improved; inner city; medication compliance

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives of the National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium (ICAC) are (1) to identify forms of immune-based therapy to promote control and prevention of asthma, (2) to design protocols to evaluate immune-based therapies in the treatment of asthma in low-income inner-city children, and (3) to determine mechanisms of immune-based therapies and the potential unique mechanisms of asthma pathogenesis in low-income inner-city children by the conduct of parallel mechanistic investigations with the therapeutic protocols.The National Asthma Education and Prevention Program (NAEPP) asthma guidelines will change with further understanding of the pathogenesis of asthma, the introduction of new medications including immunomodulators, such as anti-IgE, and the potential application of biomarkers and pharmacogenetics in the clinical management of asthma. One of the additional measures proposed in this study is the use of biomarkers, specifically the measurement of exhaled nitric oxide (eNO) using the Aerocrine NIOX device. eNO can easily be measured in less than 15 minutes. It is anticipated that using eNO measurements in addition to using the NAEPP guidelines will enhance the level of assessment of asthma, guide medication regimens, and improve overall asthma control. Studies support the role of eNO in the clinical treatment of asthma, as an added approach to improve asthma control. Exhaled nitric oxide could serve as a monitor of poor asthma control due to poor symptom recognition, poor medication adherence, and persistent inflammation. The study results may change the paradigm of management for children with persistent asthma, which could be particularly beneficial for inner city asthma children where there appear to be unique characteristics, such as allergen exposure and poor adherence to therapy, that result in persistent inflammation.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 国家过敏和感染性疾病研究所内城哮喘联盟（ICAC）的目标是（1）确定基于免疫治疗的形式，以促进基于免疫的哮喘的控制和预防，（2）设计方案，以评估基于免疫治疗的免疫疗法，以确定低收入性儿童的哮喘治疗方法，以确定基于（3）的机制，并确定不受欢迎的机制。在低收入城市内部儿童中，通过使用治疗方案进行平行的机理研究。国家哮喘教育和预防计划（NAEPP）哮喘指南将随着对哮喘的发病的进一步了解，引入新药物的引入，包括抗Ige，例如抗Ige，例如抗Ige，以及生物量管理和药物量学的应用程序。本研究提出的其他措施之一是使用生物标志物，特别是使用Aerocrine Niox设备测量呼出的一氧化氮（ENO）。 ENO可以在不到15分钟的时间内轻松测量。可以预计，除了使用NAEPP指南外，使用ENO测量结果将提高哮喘，指导药物治疗方案的评估水平，并改善整体哮喘控制。 研究支持ENO在哮喘的临床治疗中的作用，作为改善哮喘控制的另一种方法。呼出的一氧化氮可以作为症状识别不良，药物依从性和持续性炎症而导致哮喘控制不佳的监测。该研究的结果可能会改变持续性哮喘儿童的管理范式，这可能对似乎存在独特特征的内城哮喘儿童特别有益，例如过敏原暴露和对治疗的依从性不佳，这会导致持续性炎症。